# Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)

> **NCT00367237** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 115 (actual)

## Conditions studied

- Arthritis, Psoriatic

## Interventions

- **DRUG:** Infliximab + methotrexate (IFX + MTX)
- **DRUG:** Methotrexate (MTX)

## Key facts

- **NCT ID:** NCT00367237
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2017-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00367237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00367237, "Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00367237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*